Fuji Pharma Co., Ltd. (4554) AI Stock Analysis

• Market Cap: ¥32.33B
• Dividend Yield: 3.02%
• Average Volume (3M): 51.02K
• Price to Earnings (P/E): 10.3
• Beta (1Y): 0.74
• Revenue Growth: 13.46%
• EPS Growth: -46.40%
• Country: JP
• Employees: 1,658
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 12.08
• Shares Outstanding: 24,863,600
• 10 Day Avg. Volume: 46,680
• 30 Day Avg. Volume: 51,023
• PEG Ratio: -0.37
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,426.85
• Price Target Upside: 7.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: ¥1,501.00 ▲(13.28%Upside)

Fuji Pharma scores well due to its solid financial performance and attractive valuation, with a low P/E ratio and reasonable dividend yield. Technical analysis also supports a positive outlook, with potential upward momentum and oversold conditions.

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Fuji Pharma Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the commercialization of prescription medications and healthcare products to hospitals, clinics, and pharmacies. Additionally, Fuji Pharma collaborates with other pharmaceutical companies and healthcare providers for the development and distribution of its products, which can contribute to its revenue. The company may also engage in licensing agreements and partnerships, allowing it to expand its market reach and enhance its product offerings, thereby driving sales and profitability.

Fuji Pharma Co., Ltd. Financial Statement Overview

Summary

Fuji Pharma is experiencing strong revenue growth and effective cost management, as evidenced by solid gross and EBIT margins. However, the decrease in net profit margin and the volatility in cash flow indicate challenges in sustaining profitability and cash management.

Income Statement

Fuji Pharma has demonstrated strong revenue growth with a notable increase from the previous period. The gross profit margin and EBIT margin remain solid at 40.3% and 10.9%, respectively, indicating effective cost management and operational efficiency. However, the net profit margin decreased from 13.3% to 9.1% TTM, reflecting some challenges in maintaining profitability levels.

Balance Sheet

The company maintains a healthy equity ratio of 50.6%, providing a strong buffer against liabilities. The debt-to-equity ratio is stable at 0.64, suggesting moderate leverage. Return on equity is robust at 9.2%, indicating effective utilization of shareholders' funds. However, the increase in total debt highlights potential risks if not managed carefully.

Cash Flow

While operating cash flow is currently unavailable, past performance indicates some fluctuations. The free cash flow has shown significant volatility, with periods of negative free cash flow, which may impact future investment capabilities. The lack of positive free cash flow to net income ratio underscores the need for improved cash management strategies.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	46.14B	40.89B	35.43B	33.99B	33.79B
Gross Profit	17.84B	16.52B	14.56B	14.75B	14.87B
EBITDA	12.15B	7.54B	6.52B	5.46B	5.20B
Net Income	6.15B	3.44B	2.70B	2.43B	2.08B
Balance Sheet
Total Assets	90.00B	85.33B	75.54B	64.24B	61.96B
Cash, Cash Equivalents and Short-Term Investments	4.58B	2.32B	3.55B	10.20B	12.04B
Total Debt	29.25B	28.95B	24.57B	18.66B	12.19B
Total Liabilities	44.44B	44.16B	39.73B	31.56B	22.00B
Stockholders Equity	45.56B	41.17B	35.80B	32.68B	39.96B
Cash Flow
Free Cash Flow	-221.00M	-1.98B	-13.08B	2.10B	3.15B
Operating Cash Flow	4.15B	1.92B	-658.00M	5.99B	5.77B
Investing Cash Flow	-1.66B	-5.24B	-11.27B	-2.35B	-2.62B
Financing Cash Flow	-435.00M	1.92B	5.09B	-5.43B	450.00M

Fuji Pharma Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1325.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Positive. The current price of 1325 is below the 20-day moving average (MA) of 1343.50, above the 50-day MA of 1316.00, and below the 200-day MA of 1365.13, indicating a neutral trend. The MACD of 3.20 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 40.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4554.

Fuji Pharma Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4554	76 Outperform	¥32.33B	10.34	7.01%	3.02%	13.46%	-46.40%
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
TRXPF	―	$1.20B	28.25	4.56%	2.27%	―	―
TWAPF	―	$1.05B	10.01	11.38%	0.01%	―	―
MFY	―	€580.24M	17.35	4.35%	2.72%	―	―
4886	76 Outperform	¥64.00B	13.45		2.08%	2.06%	-32.48%
4569	70 Outperform	¥79.06B	9.50		0.67%	8.83%	70.61%

Fuji Pharma Co., Ltd. Corporate Events

Fuji Pharma to Acquire and Cancel Stock Acquisition Rights

Fuji Pharma Co., Ltd. has resolved to acquire and cancel all remaining stock acquisition rights from its 1st Series, originally issued to fund growth in women’s healthcare and biosimilars. This move is aimed at avoiding future dilution and will have a negligible impact on the company’s current fiscal year results, while decreasing dilutive shares by 9.8%.